



Introduction: The aim of this study was to investigate whether serum levels of interleukin-1β (IL–1β) has any possible correlation on infl ammatory 
parameters such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and fi brinogen concentration in patients with familial Mediterra-
nean fever (FMF) patients during attack-free period.
Materials and methods: The serum levels of IL-1β, as an indicator of cytokines status, and the acute phase response proteins, CRP, ESR and fi brino-
gen levels were evaluated in 35 attack-free patients with FMF and 25 healthy volunteers.
Results: Serum IL-1β levels were signifi cantly higher in patients with FMF than control subjects (P = 0.018). There was no statistically signifi cant 
diff erence in the serum levels of ESR, CRP and fi brinogen between two groups (P = 0.181, P = 0.816, P = 0.686, respectively). There was a signifi cant 
correlation between IL-1β and CRP (r = 0.513, P = 0.002) values of FMF group.
Conclusions: In conclusion, our results confi rm the presence of increased IL-1β levels in FMF patients during attack-free period. Serum IL-1β values 
seems to correlate with CRP levels. The elevation of IL-1β levels may be important in monitoring subclinical infl ammation of attack free period in FMF 
patients.
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Familial Mediterranean fever (FMF) is a group of in-
herited infl ammatory disorders that are character-
ized by recurrent episodes of fever accompanied 
by arthritis, peritonitis, pleuritis, erysipelas like ery-
thema and seen dominantly in Mediterranean 
populations (1). Mutations in MEFV gene, which 
encodes pyrin, a protein that regulates the infl am-
matory process in immune cells, were reported as 
cause of FMF disease in 1997 (2,3). The traditional 
clinical view of the disease includes repeated acute 
short-lived febrile and painful attacks with variable 
periods of remission. The patients with FMF have 
an increased acute phase response during these 
attacks and usually this increase returns to normal 
in attack-free periods. Recent studies have demon-
strated that subclinical infl ammation may contin-
ue during attack-free periods in approximately 
30% of FMF patients (4-6). The acute phase re-
sponse of infl ammation involves the increase in se-
rum level of liver-derived proteins (7). These pro-
teins have diverse functions in the infl ammatory 
process. Infl ammation accompanied by a marked 
acute phase response such as erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), se-
rum amyloid A (SAA) and fi brinogen also plays an 
important function in the initiation and progres-
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sion of FMF (5). Also, some researchers use to SAA 
protein levels as an important marker of chronic 
infl ammation in between attacks of FMF (6). Col-
chicine therapy commonly keeps from the attacks 
and related infl ammation (8).
The cytokines that are produced throughout and 
took part in infl ammatory procedure are the prin-
cipal stimulators of the manufacture of acute 
phase proteins (9). Some cytokines and their re-
ceptors have been studied in patients with remis-
sion and attack periods of FMF disease. The serum 
levels of interleukin-1β (IL-1β), tumor necrosis fac-
tor-alpha (TNF-α), soluble interleukin-2 receptor 
(sIL-2R), interleukin-6 (IL-6) and interleukin-8 (IL-8) 
have been shown to be higher in patients at the 
attack periods than remission periods and control 
groups (10-13). IL–1β levels are increased in the 
blood of patients with a multiplicity of infectious, 
immune, or traumatic situations and play a funda-
mental role in infl ammation (9). ESR is a compara-
tively nonspecifi c test that is regularly ordered 
during the diagnosis and scanning of infl ammato-
ry diseases. CRP increase is a part of the acute 
phase response at acute and chronic infl amma-
tion. It is mainly produced in the liver and released 
in six hours with increased amounts when acute 
infl ammatory stimulus began (14). Fibrinogen, a 
protein that is made in the liver excessively, is vital 
for the blood clotting process. A number of stud-
ies have been reported activated cytokine net-
work during attacks of FMF. However, cytokine ac-
tivity is not known clearly in FMF during attack-
free period. Especially, there has been no adequate 
study investigating serum IL–1β levels in patients 
with FMF in between attacks. Therefore, present 
study was performed to determine IL–1β, ESR, CRP 
and fi brinogen concentration as indicators of in-
fl ammation status and the relationship among 




This study was conducted during in the period 
from 2009 to 2010 at the Physical Medicine and 
Rehabilitation Outpatients Clinics. This study was 
approved by the local Ethics Committee. All the 
participants were informed of the study protocol 
and their written informed consents, according to 
the Declaration of Helsinki, were obtained.
In the present study groups comprised 35 FMF pa-
tients in attack-free period (male gender, N (ratio): 
10 (0.29)), and 25 age and sex matched healthy 
controls (male gender, N (ratio): 9 (0.36)). The sub-
jects aged 18-60 years were recruited in the study.
Thirty fi ve patients who fulfi lled clinical diagnostic 
criteria for FMF (15) were consecutively included in 
the study. Attack-free periods were defi ned as be-
ing free of attacks for at least 3 weeks. All of the 
patients were receiving regular colchicine treat-
ment during study (1-1.5 mg/day).
Control subjects were healthy subjects without a 
history of infl ammatory or general disease. A de-
tailed medical history was taken and clinical exam-
inations were performed on all participants. The 
healthy subjects and patients were not habituated 
to smoking and/or alcohol consumption. Patients 
with liver and kidney diseases, diabetes, peripheral 
neuropathy, familial hypercholesterolemia, thyroid 
and parathyroid diseases, hematological, lympho-
proliferative and other malignant diseases were 
excluded after this status was self-declared by the 
individuals. Aforementioned disease statuses were 
also controlled from their medical records.
Methods
All blood samples were obtained at attack-free pe-
riods and stored at -80 °C until analysis during one 
year. Fasting serum samples were collected during 
morning hours to avoid diurnal variations.
Laboratory parameters included IL-1β, ESR, CRP 
and fi brinogen. Serum IL-1β levels were measured 
with commercial (Cat. No: KAP 1211, Biosource, Bel-
gium) enzyme-linked immunosorbent assay (ELI-
SA) kits. The intra-assay and interassay coeffi  cient 
of variation percentages were declared by the 
manufacturer as 4.4% and 6.7% respectively.
ESR and CRP were determined in whole blood and 
serum aliquots, respectively. ESR was determined 
according to the Westergren method and CRP by a 
nephelometric method (Beckman Array Protein 
System, California, USA). Plasma fi brinogen levels 
were determined using commercial kits (Lot. No: 
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104470, STA-FIB, France) by STA compact autoana-
lyzer (STA, France).
Statistical analysis
Statistical analysis was performed with the Statisti-
cal Package for the Social Sciences for Windows 
(SPSS, version 15.0). Diff erences between groups 
were tested using the Mann-Whitney U test. Cor-
relation analysis between the parameters was per-
formed by Pearson’s correlation test. The results 
were presented as median and interquartile range 
(Q1-Q3). A P value below 0.05 was considered sig-
nifi cant.
Results
The demographic and clinical characteristics of 35 
FMF patients and 25 volunteer control subjects are 
shown in Table 1. There were no statistically signif-
icant diff erences between the two groups with re-
spect to demographic data. Table 2 summarizes 
laboratory fi ndings such as IL-1β, ESR, CRP and fi -
brinogen levels in the study population and con-
trol groups. The serum levels of IL-1β in attack-free 
patients with FMF were signifi cantly higher than in 
the healthy controls (P = 0.018), but not other pa-
rameters of infl ammation, including ESR, CRP and 
fi brinogen (P = 0.181, P = 0.816, P = 0.686, respec-
tively).
There was a positive correlation between serum IL-
1β and CRP (r = 0.513, P = 0.002), in patients with 
FMF. However, there were no correlations between 
IL-1β and ESR and fi brinogen.
Discussion
FMF is an autosomal recessive disorder that char-
acterized by the exacerbations and remissions (16). 
Duration and frequency are not presumable. Its 
clinical course is characterized by recurrent self-
limited attacks of fever and polyserositis at irregu-
lar intervals, accompanied with an increase in 
acute phase reactants (1,2).
Acute phase proteins, whose synthesis is altered 
during infl ammation, injury and infections, are 
probably aff ected by interleukins, released from 
the site of injury or infl ammation (17). These acute 
phase proteins comprise ESR, CRP, fi brinogen, 
SAA and alpha 1-acid glycoprotein. The major in-
ducers of acute phase proteins are IL–1, IL–6, and 
TNF-α (18).
Attacks of FMF are accompanied by an intense in-
fl ammatory response (9). In literature, elevated 
plasma concentration of acute phase reactants like 
ESR, CRP and fi brinogen and elevated serum cy-
tokines levels such as IL-1β have been determined 
during the attack periods (13,19). However, there is 
still no adequate study investigating serum IL-1β 
values in FMF patients with attack-free period. No-
tarnicola et al. (20) have investigated TNF-α, IL-1β, 
IL-6 and IL-8 cytokine expression at the transcrip-
tional level. They have reported that these param-
eters were more elevated in attack-free FMF pa-
tients than in controls. In our study, serum IL-1β 
levels are signifi cantly higher the attack-free peri-
od of FMF than the controls. In contrast to our and 
Notarnicola’s studies, Gang et al. showed that lev-
els of IL-1β were not elevated in FMF patients dur-
ing attacks or attack-free periods (18). The diff er-
ence between results may be due to the determi-
TABLE 1. The demographic and clinical features of the patients 
with FMF and healthy controls.





(N = 25) P
Male (N (ratio)) 10 (0.29) 9 (0.36) 0.542
Age (years)* 30 (20-56) 26 (21-55) 0.188
Disease duration 
(years)** 9 (3-15) - -




(N = 25) P 
IL–1 β (pg/mL) 3.35 (2.15–10.76) 2.80 (2.12–5.44) 0.018
CRP (mg/L) 4.4 (3.2–10.1) 4.6 (3.4–7.5) 0.816
ESR (mm/h) 15 (7-35) 11 (5-20) 0.181
Fibrinogen (g/L) 3.17 (2.58–4.23) 3.46 (2.57–4.29) 0.686
Data are presented as median (interquartile range); IL–1β - 
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nation time of FMF phase, age group of patients 
and processes and method of IL-1β determination. 
On the other hand, some biological variations of 
the components such as cytokines in biological 
fl uids of the human body have been reported (21). 
The confl ict results on serum IL-1β levels may also 
due to inter-individual and intra-individual biolog-
ical variation. However, these fi ndings still suggest 
a continuing pro-infl ammatory state and subclini-
cal infl ammation in attack-free period of patients 
with FMF receiving regular colchicine drug (19-22).
In the present study, ESR, CRP and fi brinogen lev-
els were not signifi cantly diff erent in patients with 
FMF at attack-free period when compared to 
healthy control group. Similar fi ndings have been 
established by other recent studies. In a previous 
study CRP levels of attack free- FMF patient were 
higher than healthy control groups (5). In our study, 
CRP levels of FMF patient were not signifi cantly 
higher than healthy controls. However, only fi ve 
patients were over the normal range.
In the literature, it was reported that approximate-
ly 30% of FMF patients have a chronic subclinical 
infl ammation with elevated acute phase reactants 
during attack free periods (6). These contradictory 
results of diff erent studies may be due to diff erent 
infl ammation phase in patients with attack free 
period.
Although our study had some limitations such as 
the small number of patients, our results suggest 
that the elevation of IL-1β levels may be important 
in monitoring subclinical infl ammation of attack 
free period in FMF patients. Further studies are 
needed to defi ne the relationship between IL-1β 
values and infl ammation in a large group of pa-
tients.
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Povezanost između koncentracije interleukina-1β u serumu i odgovora proteina 
akutne faze kod bolesnika s obiteljskom mediteranskom groznicom
Sažetak
Uvod: Cilj ovog istraživanja je ispitati postoji li korelacija između koncentracije interleukina-1β (IL-1β) s upalnim parametrima kao što su C-reak-
tivni protein (CRP) i brzina sedimentacije eritrocita (engl. erythrocyte sedimentation rate, ESR) te koncentracijom fi brinogena kod bolesnika obo-
ljelih od obiteljske mediteranske groznice (engl. familial Mediterranean fever, FMF).
Materijali i metode: Koncentracija IL-1β u serumu, kao indikator statusa citokina, i odgovor proteinske akutne faze, ESR te koncentracije CRP i 
fi brinogena određene su kod bolesnika s FMF bez napada i kod 25 zdravih ispitanika.
Rezultati: Kod bolesnika s FMF je koncentracija IL-1β u serumu bila značajno viša nego kod kontrolnih ispitanika (P = 0,018). Nije bilo statistički 
značajne razlike u brzini ESR te koncentraciji CRP i fi brinogena u serumu između skupina (P = 0,181 za ESR, P = 0,816 za CRP, P = 0,686 za fi brino-
gen). Dobivena je značajna korelacija između koncentracija IL-1β i CRP (r = 0,513, P = 0,002) u serumu u skupini bolesnika s FMF.
Zaključak: Naši rezultati potvrđuju postojanje povišene koncentracije IL-1β u serumu kod bolesnika s FMF tijekom razdoblja u kojem bolesnici 
nemaju napade. Povišenje koncentracije IL-1β moglo bi biti značajno kod promatranja prikrivenih (subkliničkih) oblika upale u razdoblju u kojem 
bolesnici oboljeli od FMF nemaju napade.
Ključne riječi: obiteljska mediteranska groznica; citokin; IL-1β; upala
